Hepatocellular carcinoma, the predominant form of primary liver cancer, is not a single disease but a collection of biologically distinct tumors that can behave very differently in the same clinical setting. This molecular diversity is one of the central challenges in modern liver-cancer care. Although targeted drugs and immunotherapies have